Clinical Trial Detail

NCT ID NCT01820325
Title Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis|Novartis Pharmaceuticals
Indications

lung squamous cell carcinoma

Therapies

Buparlisib

Age Groups: adult

No variant requirements are available.